-
UNRWA's work is at risk again Lancet (IF 98.4) Pub Date : 2024-11-20 Bassam Abu Hamad, Zeina Jamaluddine, Sarah Aly, Mohammad Salayma, Yara Asi, Hani Mowafi, Francesco Checchi, Miho Sato, Asli Bali, Paul Spiegel
No Abstract
-
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S) Lancet (IF 98.4) Pub Date : 2024-11-19 Timo E Strandberg, Petri T Kovanen, Donald M Lloyd-Jones, Frederick J Raal, Raul D Santos, Gerald F Watts
Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor for atherosclerotic cardiovascular disease. Safe and effective statins remain the cornerstone of therapeutic approach for this indication, including for children with genetic dyslipidaemia, and are one
-
The cost of not investing in the next 1000 days: implications for policy and practice Lancet (IF 98.4) Pub Date : 2024-11-18 Milagros Nores, Claudia Vazquez, Emily Gustafsson-Wright, Sarah Osborne, Jorge Cuartas, Mark J Lambiris, Dana C McCoy, Florencia Lopez-Boo, Jere Behrman, Raquel Bernal, Catherine E Draper, Anthony D Okely, Mark S Tremblay, Aisha K Yousafzai, Joan Lombardi, Günther Fink
Building on the evidence from the first paper in this Series highlighting the fundamental importance of healthy and nurturing environments for children's growth and development in the next 1000 days (ages 2–5 years), this paper summarises the benefits and costs of key strategies to support children's development in this age range. The next 1000 days build on the family-based and health-sector based
-
The first and next 1000 days: a continuum for child development in early life Lancet (IF 98.4) Pub Date : 2024-11-18 Victor M Aguayo, Pia R Britto
No Abstract
-
The next 1000 days: building on early investments for the health and development of young children Lancet (IF 98.4) Pub Date : 2024-11-18 Catherine E Draper, Aisha K Yousafzai, Dana C McCoy, Jorge Cuartas, Jelena Obradović, Sunil Bhopal, Jane Fisher, Joshua Jeong, Sonja Klingberg, Kate Milner, Lauren Pisani, Aditi Roy, Jonathan Seiden, Christopher R Sudfeld, Stephanie V Wrottesley, Günther Fink, Milagros Nores, Mark S Tremblay, Anthony D Okely
Following the first 1000 days of life that span from conception to two years of age, the next 1000 days of a child's life from 2–5 years of age offer a window of opportunity to promote nurturing and caring environments, establish healthy behaviours, and build on early gains to sustain or improve trajectories of healthy development. This Series paper, the first of a two-paper Series on early childhood
-
The obesity crisis in the USA: why are there no signs of plateauing yet? Lancet (IF 98.4) Pub Date : 2024-11-14 Sylvain Sebert
No Abstract
-
National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050 Lancet (IF 98.4) Pub Date : 2024-11-14
BackgroundOver the past several decades, the overweight and obesity epidemic in the USA has resulted in a significant health and economic burden. Understanding current trends and future trajectories at both national and state levels is crucial for assessing the success of existing interventions and informing future health policy changes. We estimated the prevalence of overweight and obesity from 1990
-
-
Glofit-GemOx: a new treatment paradigm in relapsed or refractory diffuse large B-cell lymphoma? Lancet (IF 98.4) Pub Date : 2024-11-14 Anna Sureda, Astrid Pavlosky
No Abstract
-
Health taxes: missed opportunities for health and health-care financing Lancet (IF 98.4) Pub Date : 2024-11-14 Helen Clark, Cathrine Lofthus, Robert Marten, Kumanan Rasanathan
No Abstract
-
Offline: Rediscovering a progressive America Lancet (IF 98.4) Pub Date : 2024-11-14 Richard Horton
No Abstract
-
Brazil considers obesity discrimination law Lancet (IF 98.4) Pub Date : 2024-11-14 Tony Kirby
No Abstract
-
Brazil-led G20 to target hunger, poverty, and inequities Lancet (IF 98.4) Pub Date : 2024-11-14 John Zarocostas
No Abstract
-
Elizabeth Kimani-Murage: exploring climate change and nutrition Lancet (IF 98.4) Pub Date : 2024-11-14 Udani Samarasekera
No Abstract
-
Rewriting the female body | Elizabeth Comen, All in Her Head: The Truth and Lies Early Medicine Taught Us About Women's Bodies and Why It Matters Today, Harper Wave/HarperCollins (2024), p. 368, US$32·00, ISBN: 9780063293014 Lancet (IF 98.4) Pub Date : 2024-11-14 Gabriel Weston
No Abstract
-
James Baldwin: ignorance, power, justice Lancet (IF 98.4) Pub Date : 2024-11-14 Seye Abimbola
No Abstract
-
Thomas Killip III Lancet (IF 98.4) Pub Date : 2024-11-14 Geoff Watts
Download: Download high-res image (307KB) Download: Download full-size image
-
Misinformation targeting replicon vaccine recipients: an urgent public health ethical issue Lancet (IF 98.4) Pub Date : 2024-11-14 Hiroyasu Ino, Yoshiyuki Takimoto, Eisuke Nakazawa
No Abstract
-
Refugees and asylees with disabilities: a call for economic integration Lancet (IF 98.4) Pub Date : 2024-11-14 Mustafa Rfat, Josephine Nabayinda, Samuel Kizito, Mansha Mirza
No Abstract
-
Problems in defining medicalised FGM and proposed solutions Lancet (IF 98.4) Pub Date : 2024-11-14 Arianne Shahvisi, Jasmine Abdulcadir, Mireia Garcés de Marcilla, Tammary Chepkoech Rotich, Brian D Earp
No Abstract
-
Nakalanga syndrome and hypopituitarism Lancet (IF 98.4) Pub Date : 2024-11-14 Benjamin De Wilde, Robert Colebunders
No Abstract
-
Department of Error Lancet (IF 98.4) Pub Date : 2024-11-14
Park S-J, Ahn J-M, Kang D-Y, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet 2024; 403: 1753–65—In table 2 of this Article, the proportion of patients in the optimal medical therapy group with target-vessel-related myocardial
-
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial Lancet (IF 98.4) Pub Date : 2024-11-14 Jeremy S Abramson, Matthew Ku, Mark Hertzberg, Hui-Qiang Huang, Christopher P Fox, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Haifaa Abdulhaq, William Townsend, Charles Herbaux, Jan M Zaucha, Qing-Yuan Zhang, Hung Chang, Yanyan Liu, Chan Yoon Cheah, Herve Ghesquieres, Stephen Simko, Victor Orellana-Noia, Richard Ta, Gareth P Gregory
BackgroundGlofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a second-line therapy. We investigated the efficacy and safety of glofitamab plus gemcitabine–oxaliplatin (Glofit-GemOx) versus rituximab (R)-GemOx in patients with relapsed or refractory diffuse
-
Central conducting lymphatic anomaly with pulmonary lymphatic dysplasia causes restrictive lung disease and chronic pleural effusion Lancet (IF 98.4) Pub Date : 2024-11-14 Mudit Gupta, Ganesh Krishnamurthy, Christopher L Smith
Section snippets ContributorsWe all provided care for the patient and contributed equally to the acquisition of the images, and the preparation and editing of the manuscript. Written consent for publication was obtained from the patient. Declaration of interestsWe declare no competing interests. AcknowledgementsJill and Mark Fishman Center for Lymphatic Disorders (MG, GK, and CLS) and National Heart
-
Oesophageal cancer Lancet (IF 98.4) Pub Date : 2024-11-14 Hong Yang, Feng Wang, Christopher L Hallemeier, Toni Lerut, Jianhua Fu
Oesophageal cancer is the seventh leading cause of cancer mortality worldwide. Two major pathological subtypes exist: oesophageal squamous cell carcinoma and oesophageal adenocarcinoma. Epidemiological studies in the last decade have shown a gradual increase in the incidence of oesophageal adenocarcinoma worldwide. The prognosis of oesophageal cancer has greatly improved due to breakthroughs in screening
-
Cardiogenic shock Lancet (IF 98.4) Pub Date : 2024-11-14 Enzo Lüsebrink, Leonhard Binzenhöfer, Marianna Adamo, Roberto Lorusso, Alexandre Mebazaa, David A Morrow, Susanna Price, Jacob C Jentzer, Daniel Brodie, Alain Combes, Holger Thiele
Cardiogenic shock is a complex syndrome defined by systemic hypoperfusion and inadequate cardiac output arising from a wide array of underlying causes. Although the understanding of cardiogenic shock epidemiology, specific subphenotypes, haemodynamics, and cardiogenic shock severity staging has evolved, few therapeutic interventions have shown survival benefit. Results from seminal randomised controlled
-
Divisions over the regulation of lecanemab Lancet (IF 98.4) Pub Date : 2024-11-14 Bart De Strooper, Christian Haass, John Hardy, Henrik Zetterberg
No Abstract
-
Amyloid-lowering treatment in Alzheimer's disease Lancet (IF 98.4) Pub Date : 2024-11-14 Frank Jessen, Lutz Frölich, Jakub Hort, Bengt Winblad, Juan Fortea
No Abstract
-
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges Lancet (IF 98.4) Pub Date : 2024-11-14 Michael T Heneka, David Morgan, Frank Jessen
With the advent of the first disease-modifying, anti-amyloid β-directed passive immunotherapy for Alzheimer's disease, questions arise who, when, and how to treat. This paper describes shortly the pathogenic basis of and preclinical data, which have, more than two decades ago, initiated the development of this vaccination therapy. We discuss clinical trial results of aducanumab, lecanemab, and donanemab
-
Rising diabetes, lagging treatment, and the need for better systems Lancet (IF 98.4) Pub Date : 2024-11-13 Leonor Guariguata, Natasha Sobers
No Abstract
-
Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants Lancet (IF 98.4) Pub Date : 2024-11-13
BackgroundDiabetes can be detected at the primary health-care level, and effective treatments lower the risk of complications. There are insufficient data on the coverage of treatment for diabetes and how it has changed. We estimated trends from 1990 to 2022 in diabetes prevalence and treatment for 200 countries and territories. MethodsWe used data from 1108 population-representative studies with 141
-
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial Lancet (IF 98.4) Pub Date : 2024-11-12 Yvonne M Mowery, Karla V Ballman, Angela M Hong, Scott M Schuetze, Andrew J Wagner, Varun Monga, Rachel S Heise, Steven Attia, Edwin Choy, Melissa A Burgess, Susie Bae, David I Pryor, Brian A Van Tine, Gabriel Tinoco, Bartosz Chmielowski, Carolyn Freeman, Alessandro Gronchi, Christian F Meyer, Mark A Dickson, Lee Hartner, David G Kirsch
BackgroundApproximately half of patients with localised, high-risk soft tissue sarcoma of the extremity develop metastases. We aimed to assess whether the addition of pembrolizumab to preoperative radiotherapy and surgery would improve disease-free survival. MethodsWe completed an open-label, randomised clinical trial in patients with grade 2 or 3, stage III undifferentiated pleomorphic sarcoma or
-
Evaluating the benefits of the early use of GLP-1 receptor agonists Lancet (IF 98.4) Pub Date : 2024-11-12 Peter-James H Zushin, Joseph C Wu
No Abstract
-
Integrative medicine for the treatment of stroke Lancet (IF 98.4) Pub Date : 2024-11-12 Simiao Wu
No Abstract
-
Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial Lancet (IF 98.4) Pub Date : 2024-11-12 Jianwen Guo, Xiaoying Chen, Manli Wu, Dou Wang, Yang Zhao, Qiang Li, Guanghai Tang, Fengyuan Che, Zhangyong Xia, Zai Liang, Liu Shi, Qiuhua Jiang, Yajie Chen, Xiaoqiu Liu, Xinwen Ren, Menglu Ouyang, Borui Wang, Shoujiang You, Laurent Billot, Xia Wang, Mingfei Li
BackgroundThere are few proven treatments for acute spontaneous intracerebral haemorrhage, and they all target reducing expansion of the haematoma. The traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao) in an oral solution is comprised of several Chinese herbs that are widely used to treat patients with intracerebral haemorrhage in China on the understanding that they enhance resorption of the
-
Perioperative immunotherapy in soft tissue sarcomas Lancet (IF 98.4) Pub Date : 2024-11-12 Antoine Italiano
No Abstract
-
Scientific consideration of sex and gender is the responsibility of the many, not the few Lancet (IF 98.4) Pub Date : 2024-11-11 Alice Witt, Robyn Norton, Mark Woodward, Kate Womersley
No Abstract
-
Mobilising the health community to protect health care from attack Lancet (IF 98.4) Pub Date : 2024-11-11 Martin Chalfie, Leonard Rubenstein, Lujain Alqodmani, Georges C Benjamin, Pamela F Cipriano, Carlos del Rio, Victor J Dzau, Timothy Johnson, Robert S Lawrence, Michele Heisler
No Abstract
-
Mexico Summit 20 years on—gains and challenges Lancet (IF 98.4) Pub Date : 2024-11-10 Tikki Pang, Ulysses Panisset, Francisco Becerra-Posada, Julio Frenk
No Abstract
-
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial Lancet (IF 98.4) Pub Date : 2024-11-08 Janet L Kwiatkowski, Mark C Walters, Suradej Hongeng, Evangelia Yannaki, Andreas E Kulozik, Joachim B Kunz, Martin G Sauer, Adrian J Thrasher, Isabelle Thuret, Ashutosh Lal, Ge Tao, Shamshad Ali, Himal L Thakar, Heidi Elliot, Ankit Lodaya, Ji Lee, Richard A Colvin, Franco Locatelli, Alexis A Thompson
BackgroundTransfusion-dependent β-thalassaemia (TDT) is a severe disease, resulting in lifelong blood transfusions, iron overload, and associated complications. Betibeglogene autotemcel (beti-cel) gene therapy uses autologous haematopoietic stem and progenitor cells (HSPCs) transduced with BB305 lentiviral vector to enable transfusion independence. MethodsHGB-212 was a non-randomised, multicentre,
-
Japan's lonely deaths: a social epidemic Lancet (IF 98.4) Pub Date : 2024-11-08 Megan Tatum
No Abstract
-
Identifying groups with the greatest need for interventions to improve wellbeing Lancet (IF 98.4) Pub Date : 2024-11-07 Farah Allouch, Katherine T Mills
No Abstract
-
Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008–21: an analysis using the Human Development Index Lancet (IF 98.4) Pub Date : 2024-11-07 Laura Dwyer-Lindgren, Parkes Kendrick, Mathew M Baumann, Zhuochen Li, Chris Schmidt, Dillon O Sylte, Farah Daoud, Wichada La Motte-Kerr, Robert W Aldridge, Catherine Bisignano, Simon I Hay, Ali H Mokdad, Christopher J L Murray
BackgroundThe Human Development Index (HDI)—a composite metric encompassing a population's life expectancy, education, and income—is used widely for assessing and comparing human development and wellbeing at the country level, but does not account for within-country inequality. In this study of the USA, we aimed to adapt the HDI framework to measure the HDI at an individual level to examine disparities
-
Addressing transnational exploitation and armed conflict in the response to mpox Lancet (IF 98.4) Pub Date : 2024-11-07 Jirair Ratevosian, Michele Heisler, Tom Carpino, Thomas McHale, Joyeux Mushekuru, Chris Beyrer
No Abstract
-
-
Mpox surveillance: the need for enhanced testing and genomic epidemiology Lancet (IF 98.4) Pub Date : 2024-11-07 Jeremy R Wang
No Abstract
-
Offline: Being one of the lucky ones Lancet (IF 98.4) Pub Date : 2024-11-07 Richard Horton
No Abstract
-
-
-
Marina Romanello: tracking climate change and health Lancet (IF 98.4) Pub Date : 2024-11-07 Aarathi Prasad
No Abstract
-
A history of hydrotherapy and mental health Lancet (IF 98.4) Pub Date : 2024-11-07 Matthew Smith
No Abstract
-
-
Violence against women and girls in Sudan's conflict zones Lancet (IF 98.4) Pub Date : 2024-11-07 Ibrahim Nagmeldin Hassan
No Abstract
-
Sparsentan and kidney protection: improved medullary oxygenation? Lancet (IF 98.4) Pub Date : 2024-11-07 Dion Groothof, Reinold O B Gans, Stephan J L Bakker
No Abstract
-
Sparsentan and kidney protection: improved medullary oxygenation? – Authors' reply Lancet (IF 98.4) Pub Date : 2024-11-07 Donald Kohan, Jula Inrig, Brad H Rovin, Radko Komers
No Abstract
-
Adjuvant everolimus after renal cell carcinoma nephrectomy Lancet (IF 98.4) Pub Date : 2024-11-07 Yao-Ning Feng, Li Xiao, Guang-Yu Xie
No Abstract
-
Adjuvant everolimus after renal cell carcinoma nephrectomy – Authors' reply Lancet (IF 98.4) Pub Date : 2024-11-07 Christopher W Ryan, Catherine M Tangen, Primo N Lara
No Abstract
-
Treatment of vulnerable atherosclerotic plaques: the PREVENT trial Lancet (IF 98.4) Pub Date : 2024-11-07 Giuseppe Ferrante, Gianluca Mincione, Antonio Colombo
No Abstract
-
Treatment of vulnerable atherosclerotic plaques: the PREVENT trial Lancet (IF 98.4) Pub Date : 2024-11-07 Kyriakos Dimitriadis, Nikolaos Pyrpyris, Konstantinos Tsioufis
No Abstract
-
Treatment of vulnerable atherosclerotic plaques: the PREVENT trial Lancet (IF 98.4) Pub Date : 2024-11-07 Chinmay Khandkar, Jordan Fulcher, Sanjay Patel, Anthony Keech
No Abstract